PharmAthene, Inc.  

(Public, NYSEMKT:PIP)   Watch this stock  
Find more results for NYSEAMEX:PIP
1.62
Apr 24 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.19 - 2.59
Open     -
Vol / Avg. 0.00/102,379.00
Mkt cap 103.09M
P/E     -
Div/yield     -
EPS -0.17
Shares 63.63M
Beta 1.89
Inst. own 42%
Mar 9, 2015
Full Year 2014 PharmAthene Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -143.97% -97.70%
Operating margin -143.65% -100.01%
EBITD margin - -98.54%
Return on average assets -46.53% -50.90%
Return on average equity -57.98% -77.75%
Employees 35 -
CDP Score - -

Address

1 Park Pl Ste 450
ANNAPOLIS, MD 21401-3481
United States - Map
+1-410-2692600 (Phone)
+1-410-2692601 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

PharmAthene, Inc. is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical threats. The Company�s biodefense portfolio of product candidates include SparVax, a second generation recombinant protective antigen (rPA) anthrax vaccine; Valortim, a fully human monoclonal antibody for the prevention and treatment of anthrax infection, and rBChE (recombinant butyrylcholinesterase) bioscavanger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides. SparVax is a second generation, rPA anthrax vaccine designed to protect against inhalational anthrax, the most lethal form of B. anthracis infection in humans. Valortim is a fully human monoclonal antibody designed to protect against and treat human inhalational anthrax, as both post-exposure prophylaxis and post-exposure therapy.

Officers and directors

Mitchel B. Sayare Ph.D. Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Linda L. Chang Chief Financial Officer, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Francesca M. Cook Senior Vice President - Policy and Government Affairs
Age: 49
Bio & Compensation  - Reuters
Wayne Morges Ph.D. Senior Vice President - Regulatory Affairs and Quality
Age: 67
Bio & Compensation  - Reuters
Arthur Y. Elliott Ph.D. Acting Chief Scientific Officer
Age: 78
Bio & Compensation  - Reuters
Eric I. Richman Director
Age: 53
Bio & Compensation  - Reuters
John M. Gill Independent Director
Age: 62
Bio & Compensation  - Reuters
Jeffrey W. Runge M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Derace Lan Schaffer M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Steven St. Peter M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters